Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 11, 2006, Pages 4593-4598

  Pollard, Patrick J ^a   El Bahrawy, Mona ^b   Poulsom, Richard ^a   Elia, George ^a   Killick, Pip ^e   Kelly, Gavin ^a   Hunt, Toby ^a   Jeffery, Rosemary ^a   Seedhar, Pooja ^a   Barwell, Julian ^d   Latif, Farida ^e   Gleeson, Michael J ^c   Hodgson, Shirley V ^d   Stamp, Gordon W ^b   Tomlinson, Ian P M ^a   Maher, Eamonn R ^e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CLUSTERIN; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN BNIP3; PROTEIN JUNB; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE COMPLEX 2 SUBUNIT B; SUCCINATE DEHYDROGENASE D; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; HIF1A PROTEIN, HUMAN; MOP2 PROTEIN, HUMAN; VHL PROTEIN, HUMAN;

ADRENAL MEDULLA; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADRENAL TUMOR; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33751530026     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0920     Document Type: Article

References (39)

1. Maher ER, Eng C 2002 The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11:2347-2354
2. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery 3rd WH, Myers EN, Ferrell RE, Rubinstein WS 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183
3. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard 3rd CW, Cornelisse CJ, Devilee P, Devlin B 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851
4. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER 2001 Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54
5. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER 2001 Germline SDHD mutation in familial phaeochromocytoma. Lancet 357:1181-1182
6. Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA, Maher ER 1997 Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 6:1051-1056
7. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E 2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-αprolyl hydroxylase. Cancer Cell 7:77-85
8. Maxwell PH 2005 A common pathway for genetic events leading to pheochromocytoma. Cancer Cell 8:91-93
9. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8:155-167
10. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP 2005 Accumulation of Krebs cycle intermediates and overexpression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
11. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P, Rotig A, Jeunemaitre X 2001 The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69:1186-1197
12. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
13. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH 2000 Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741
14. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ 2001 Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472
15. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin Jr WG 2001 HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-468
16. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11:897-911
17. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD 2005 A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72-80
18. Neumann HP 1995 von Hippel-Lindau syndrome: a rare syndrome as the clue for the molecular basis of common renal disorders. Nephrol Dial Transplant 10:1498-1499
19. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin Jr WG 2001 von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027
20. Crossey PA, Eng C, Ginalska-Malinowska M, Lennard TW, Wheeler DC, Ponder BA, Maher ER 1995 Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 32:885-886
21. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER 2001 Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038
22. Pollard P, Wortham N, Barclay E, Alam A, Elia G, Manek S, Poulsom R, Tomlinson I 2005 Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 205:41-49
23. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR 1992 Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220
24. Team RDC 2005 A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing
25. Venables WN, Ripley BD 2002 Modern applied statistics with R. 4th ed. Springer-Verlag: Berlin
26. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin Jr WG 1998 Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732-741
27. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM 1996 Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589-10594
28. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ 2005 Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686
29. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG 2002 Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246
30. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD 2002 The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255
31. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH 2002 HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468
32. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER 2002 Identification of CCND1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of CCND1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811
33. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD 2002 VHL-mediated hypoxia regulation of CCND1 in renal carcinoma cells. Cancer Res 62:3014-3019
34. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N, Takahashi M 2002 Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161:249-256
35. Richards FM, Schofield PN, Fleming S, Maher ER 1996 Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5:639-644
36. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS 2004 BNIP3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6:597-609
37. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621
38. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951
39. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nose V, Kaelin Jr WG 2006 CLU is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168:574-584